Triglycerides, medium chain; triglycerides, long chain
Brand: Betaquik; Carbzero
PBAC's latest decision on Triglycerides, medium chain; triglycerides, long chain: Not recommended (2017). Considered for Betaquik: dietary management of conditions requiring a source of medium chain triglycerides (chylous ascites, chylothorax, hyperlipoproteinaemia type 1, long chain fatty acid oxidation disorders, fat malabsorption due to liver disease, short gut syndrome, cystic fibrosis, or gastrointestinal disorders) or ketogenic diet (intractable seizures, glucose transport protein defect, pyruvate dehydrogenase deficiency). Carbzero: ketogenic diet (intractable seizures, glucose transport protein defect, pyruvate dehydrogenase deficiency).
PBAC outcome
Not recommended
Restricted
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
1
first 2017
Submissions
1
2017 → 2017
Eligible population
Patients requiring dietary management of conditions requiring a source of medium chain triglycerides (chylous ascites, chylothorax, hyperlipoproteinaemia type 1, long chain fatty acid oxidation disorders, fat malabsorption due to liver disease, short gut syndrome, cystic fibrosis, or gastrointestinal disorders) or ketogenic diet (intractable seizures, glucose transport protein defect, pyruvate dehydrogenase deficiency).
Therapy area
Metabolic
Line of therapy
Not applicable
Evidence base
Cost-minimisation
Primary endpoint
Cost-minimisation
Economic model
Cost-minimisation
ICER note
Cost-minimisation analysis presented; no traditional ICER calculated. This is a minor submission for a reformulation/repackaging of existing listed products.
Why PBAC said no
Reasons cited in the latest PSD: Increase in maximum quantity per script not clinically appropriate; would increase total volume per script from 9 L to 10.125 L resulting in higher PBS costs; NPWP did not support the proposed amendment